{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:31:45Z","timestamp":1762918305336,"version":"3.40.5"},"reference-count":155,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>With the advent of ivermectin, tremendous improvement in public health has been observed, especially in the treatment of onchocerciasis and lymphatic filariasis that created chaos mostly in rural, sub-Saharan Africa and Latin American countries. The discovery of ivermectin became a boon to millions of people that had suffered in the pandemic and still holds its pharmacological potential. Ivermectin continued to surprise scientists because of its notable role in the treatment of various other tropical diseases (Chagas, leishmaniasis, worm infections, etc.) and is viewed as the safest drug with the least toxic effects. The current review highlights its role in unexplored avenues towards forging ahead of the repositioning of this multitargeted drug in cancer, viral (the evaluation of the efficacy of ivermectin against SARS-Cov-2 is under investigation) and bacterial infection and malaria. This article also provides a glimpse of regulatory considerations of drug repurposing and current formulation strategies. Due to its broad-spectrum activity, multitargeted nature and promising efforts are put towards the repurposing of this drug throughout the field of medicine. This single drug originated from a microbe, changed the face of global health by proving its unmatched success and progressive efforts continue in maintaining its bequestnin the management of global health by decreasing the burden of various diseases worldwide.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567201819666220516163242","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:55:20Z","timestamp":1652774120000},"page":"1049-1066","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Forging Ahead the Repositioning of Multitargeted Drug Ivermectin"],"prefix":"10.2174","volume":"20","author":[{"given":"Srividya","family":"Atmakuri","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Nene","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmendra","family":"Khatri","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashi Bala","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.R.","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4363","authenticated-orcid":true,"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2174\/1381612033455279","volume":"9","author":"Workman P.","year":"2003","unstructured":"Workman P.; How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003,9(11),891-902","journal-title":"Curr Pharm Des"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nrmicro1048","volume":"2","author":"\u00d5mura S.","year":"2004","unstructured":"\u00d5mura S.; Crump A.; The life and times of ivermectin - a success story. Nat Rev Microbiol 2004,2(12),984-989","journal-title":"Nat Rev Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/AAC.15.3.361","volume":"15","author":"Burg R.W.","year":"1979","unstructured":"Burg R.W.; Miller B.M.; Baker E.E.; Birnbaum J.; Currie S.A.; Hartman R.; Kong Y-L.; Monaghan R.L.; Olson G.; Putter I.; Tunac J.B.; Wallick H.; Stapley E.O.; Oiwa R.; Omura S.; Avermectins, new family of potent anthelmintic agents: Producing organism and fermentation. Antimicrob Agents Chemother 1979,15(3),361-367","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","volume":"31","author":"Omura S.","year":"2008","unstructured":"Omura S.; Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008,31(2),91-98","journal-title":"Int J Antimicrob Agents"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2183\/pjab.87.13","volume":"87","author":"Crump A.","year":"2011","unstructured":"Crump A.; \u014cmura S.; Ivermectin, \u2018wonder drug\u2019 from Japan: The human use perspective. Proc Jpn Acad, Ser B, Phys Biol Sci 2011,87(2),13-28","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=6","first-page":"1","volume":"51","author":"Sainas S.","year":"2018","unstructured":"Sainas S.; Dosio F.; Boschi D.; Lolli M.L.; Targeting human onchocerciasis: Recent advances beyond ivermectin. Annu Rep Med Chem 2018,51,1-38","journal-title":"Annu Rep Med Chem"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1179\/136485908X337436","volume":"102","author":"Amazigo U.","year":"2008","unstructured":"Amazigo U.; The African programme for onchocerciasis control (APOC). Ann Trop Med Parasitol 2008,102(1),19-22","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1756-3305-5-28","volume":"5","author":"Tekle A.H.","year":"2012","unstructured":"Tekle A.H.; Elhassan E.; Isiyaku S.; Amazigo U.V.; Bush S.; Noma M.; Cousens S.; Abiose A.; Remme J.H.; Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: First evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors 2012,5(1),28","journal-title":"Parasit Vectors"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/cix1069","volume":"66","author":"Repetto S.A.","year":"2018","unstructured":"Repetto S.A.; Ruybal P.; Batalla E.; L\u00f3pez C.; Fridman V.; Sierra M.; Radisic M.; Bravo P.M.; Risso M.G.; Gonz\u00e1lez Cappa S.M.; Alba S.C.D.; Strongyloidiasis outside endemic areas: Long-term parasitological and clinical follow-up after ivermectin treatment. Clin Infect Dis 2018,66(10),1558-1565","journal-title":"Clin Infect Dis"},{"key":"ref=10","first-page":"35","volume":"81","author":"Belizario V.Y.","year":"2003","unstructured":"Belizario V.Y.; Amarillo M.E.; de Leon W.U.; de los Reyes A.E.; Bugayong M.G.; Macatangay B.J.; A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003,81(1),35-42","journal-title":"Bull World Health Organ"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":", e0006825.","DOI":"10.1371\/journal.pntd.0006825","volume":"12","author":"Coscione S.","year":"2018","unstructured":"Coscione S.; Esau T.; Kekeubata E.; Diau J.; Asugeni R.; MacLaren D.; Steer A.C.; Kositz C.; Marks M.; Impact of ivermectin administered for scabies treatment on the prevalence of head lice in Atoifi, Solomon Islands. PLoS Negl Trop Dis 2018,12(9),, e0006825.","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","volume":"33","author":"Laing R.","year":"2017","unstructured":"Laing R.; Gillan V.; Devaney E.; Ivermectin - Old drug, new tricks? Trends Parasitol 2017,33(6),463-472","journal-title":"Trends Parasitol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0190-9622(00)90131-2","volume":"42","author":"Usha V.","year":"2000","unstructured":"Usha V.; Gopalakrishnan Nair T.V.; A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000,42(2 Pt 1),236-240","journal-title":"J Am Acad Dermatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jpba.2005.08.026","volume":"40","author":"Kitzman D.","year":"2006","unstructured":"Kitzman D.; Wei S-Y.; Fleckenstein L.; Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies. J Pharm Biomed Anal 2006,40(4),1013-1020","journal-title":"J Pharm Biomed Anal"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4612-3626-9_7","author":"Fink D.W.","year":"1989","unstructured":"Fink D.W.; Porras A.G.; Ivermectin and Abamectin 1989,113-130","journal-title":"Ivermectin and Abamectin"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","volume":"10","author":"Gonz\u00e1lez Canga A.","year":"2008","unstructured":"Gonz\u00e1lez Canga A.; Sahag\u00fan Prieto A.M.; Diez Li\u00e9bana M.J.; Fern\u00e1ndez Mart\u00ednez N.; Sierra Vega M.; Garc\u00eda Vieitez J.J.; The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J 2008,10(1),42-46","journal-title":"AAPS J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","volume":"16","author":"Chaccour C.","year":"2017","unstructured":"Chaccour C.; Hammann F.; Rabinovich N.R.; Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J 2017,16(1),161","journal-title":"Malar J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijpddr.2011.10.001","volume":"2","author":"Lespine A.","year":"2011","unstructured":"Lespine A.; M\u00e9nez C.; Bourguinat C.; Prichard R.K.; P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist 2011,2,58-75","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","volume":"42","author":"Cynthia A.","year":"2002","unstructured":"Cynthia A.; Lasseter, safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002,42,1122-1133","journal-title":"J Clin Pharmacol"},{"key":"ref=20","first-page":"325","volume":"15","author":"Kircik L.H.","year":"2016","unstructured":"Kircik L.H.; Del Rosso J.Q.; Layton A.M.; Schauber J.; Over 25 years of clinical experience with ivermectin: An overview of safety for an increasing number of indications. J Drugs Dermatol 2016,15(3),325-332","journal-title":"J Drugs Dermatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2165\/00003495-199142040-00007","volume":"42","author":"Goa K.L.","year":"1991","unstructured":"Goa K.L.; McTavish D.; Clissold S.P.; Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs 1991,42(4),640-658","journal-title":"Drugs"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/QCO.0b013e328010774c","volume":"19","author":"Fox L.M.","year":"2006","unstructured":"Fox L.M.; Ivermectin: Uses and impact 20 years on. Curr Opin Infect Dis 2006,19(6),588-593","journal-title":"Curr Opin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(89)90136-0","volume":"1","author":"Rothova A.","year":"1989","unstructured":"Rothova A.; van der Lelij A.; Stilma J.S.; Wilson W.R.; Barbe R.F.; Side-effects of ivermectin in treatment of onchocerciasis. Lancet 1989,1(8652),1439-1441","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMc1917344","volume":"383","author":"Baudou E.","year":"2020","unstructured":"Baudou E.; Lespine A.; Durrieu G.; Andr\u00e9 F.; Gandia P.; Durand C.; Cunat S.; Serious ivermectin toxicity and human ABCB1 non-sense mutations. N Engl J Med 2020,383(8),787-789","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2002.12.002","volume":"277","author":"Benet L.Z.","year":"2004","unstructured":"Benet L.Z.; Cummins C.L.; Wu C.Y.; Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004,277(1-2),3-9","journal-title":"Int J Pharm"},{"key":"ref=26","first-page":"405","author":"Eberhard M.","year":"2013","unstructured":"Eberhard M.; Progress toward elimination of onchocerciasis in the Americas \u2014 1993\u20132012 2013,405-408","journal-title":"Progress toward elimination of onchocerciasis in the Americas \u2014 1993\u20132012"},{"key":"ref=27","unstructured":"World Health Organization Onchocerciasis. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/onchocerciasis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1179\/000349802125000826","volume":"96","author":"Murdoch M.E.","year":"2002","unstructured":"Murdoch M.E.; Asuzu M.C.; Hagan M.; Makunde W.H.; Ngoumou P.; Ogbuagu K.F.; Okello D.; Ozoh G.; Remme J.; Onchocerciasis: The clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002,96(3),283-296","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.81692","volume":"3","author":"Winthrop K.L.","year":"2011","unstructured":"Winthrop K.L.; Furtado J.M.; Silva J.C.; Resnikoff S.; Lansingh V.C.; River blindness: An old disease on the brink of elimination and control. J Glob Infect Dis 2011,3(2),151-155","journal-title":"J Glob Infect Dis"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00105-015-3735-5","volume":"67","author":"Gonser L.","year":"2016","unstructured":"Gonser L.; Gonser C.; Schaller M.; Pathogenesis, clinical picture, and current therapy of rosacea. Der Hautarzt. Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete 2016,67(1),69-82","journal-title":"Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1475-2883-2-S1-S5","volume":"2","author":"Mackenzie C.D.","year":"2003","unstructured":"Mackenzie C.D.; Geary T.G.; Gerlach J.A.; Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J 2003,2(1)(Suppl. 1),S5","journal-title":"Filaria J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1473-3099(16)30544-8","volume":"17","author":"Ndeffo-Mbah M.L.","year":"2017","unstructured":"Ndeffo-Mbah M.L.; Galvani A.P.; Global elimination of lymphatic filariasis. Lancet Infect Dis 2017,17(4),358-359","journal-title":"Lancet Infect Dis"},{"key":"ref=33","first-page":", CD002219.","volume":"2012","author":"Ejere H.O.","year":"2012","unstructured":"Ejere H.O.; Schwartz E.; Wormald R.; Evans J.R.; Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev 2012,2012(8),, CD002219.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","volume":"62","author":"Thomsen E.K.","year":"2016","unstructured":"Thomsen E.K.; Sanuku N.; Baea M.; Satofan S.; Maki E.; Lombore B.; Schmidt M.S.; Siba P.M.; Weil G.J.; Kazura J.W.; Flecken-stein L.L.; King C.L.; Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016,62(3),334-341","journal-title":"Clin Infect Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-3024.2005.00792.x","volume":"27","author":"Hoerauf A.","year":"2005","unstructured":"Hoerauf A.; Satoguina J.; Saeftel M.; Specht S.; Immunomodulation by filarial nematodes. Parasite Immunol 2005,27(10-11),417-429","journal-title":"Parasite Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1086\/599090","volume":"199","author":"Babu S.","year":"2009","unstructured":"Babu S.; Kumaraswami V.; Nutman T.B.; Alternatively activated and immunoregulatory monocytes in human filarial infections. J Infect Dis 2009,199(12),1827-1837","journal-title":"J Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/2229-5070.138544","volume":"4","author":"Mahalingashetti P.B.","year":"2014","unstructured":"Mahalingashetti P.B.; Subramanian R.A.; Jayker S.S.; Vijay A.; Lymphatic filariasis: A view at pathological diversity. Trop Parasitol 2014,4(2),128-132","journal-title":"Trop Parasitol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4269\/ajtmh.2009.80.956","volume":"80","author":"Debrah A.Y.","year":"2009","unstructured":"Debrah A.Y.; Mand S.; Marfo-Debrekyei Y.; Batsa L.; Pfarr K.; Lawson B.; Taylor M.; Adjei O.; Hoerauf A.; Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg 2009,80(6),956-963","journal-title":"Am J Trop Med Hyg"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0065-308X(05)60004-8","volume":"60","author":"Taylor M.J.","year":"2005","unstructured":"Taylor M.J.; Bandi C.; Hoerauf A.; Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005,60,245-284","journal-title":"Adv Parasitol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/000349809X12502035776513","volume":"103","author":"Hooper P.","year":"2009","unstructured":"Hooper P.; Bradley M.; Biswas G.; Ottesen E.; The global programme to eliminate lymphatic filariasis: Health impact during its first 8 years (2000\u20132007). Ann Trop Med Parasitol 2009,103(1),17-21","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1017\/S0031182005008218","volume":"131","author":"Wolstenholme A.J.","year":"2005","unstructured":"Wolstenholme A.J.; Rogers A.T.; Glutamate-gated chloride channels and the mode of action of the avermectin\/milbemycin anthelmintics. Parasitology 2005,131(S1)(Suppl.),S85-S95","journal-title":"Parasitology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","volume":"376","author":"Taylor M.J.","year":"2010","unstructured":"Taylor M.J.; Hoerauf A.; Bockarie M.; Lymphatic filariasis and onchocerciasis. Lancet 2010,376(9747),1175-1185","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1179\/000349803235001697","volume":"97","author":"Awadzi K.","year":"2003","unstructured":"Awadzi K.; Edwards G.; Duke B.O.; Opoku N.O.; Attah S.K.; Addy E.T.; Ardrey A.E.; Quartey B.T.; The co-administration of ivermectin and albendazole- safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol 2003,97(2),165-178","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.pt.2010.02.010","volume":"26","author":"Van den Bossche P.","year":"2010","unstructured":"Van den Bossche P.; de La Rocque S.; Hendrickx G.; Bouyer J.; A changing environment and the epidemiology of tsetse-transmitted livestock trypanosomiasis. Trends Parasitol 2010,26(5),236-243","journal-title":"Trends Parasitol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-3024.2011.01286.x","volume":"33","author":"Morrison L.J.","year":"2011","unstructured":"Morrison L.J.; Parasite-driven pathogenesis in Trypanosoma brucei infections. Parasite Immunol 2011,33(8),448-455","journal-title":"Parasite Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":", e55.","DOI":"10.1371\/journal.pmed.0050055","volume":"5","author":"Simarro P.P.","year":"2008","unstructured":"Simarro P.P.; Jannin J.; Cattand P.; Eliminating human African trypanosomiasis: Where do we stand and what comes next? PLoS Med 2008,5(2),, e55.","journal-title":"PLoS Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"Brun R.","year":"2010","unstructured":"Brun R.; Blum J.; Chappuis F.; Burri C.; Human African trypanosomiasis. Lancet 2010,375(9709),148-159","journal-title":"Lancet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1172\/JCI200421052","volume":"113","author":"Kennedy P.G.","year":"2004","unstructured":"Kennedy P.G.; Human African trypanosomiasis of the CNS: Current issues and challenges. J Clin Invest 2004,113(4),496-504","journal-title":"J Clin Invest"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/0035-9203(95)90673-8","volume":"89","author":"P\u00e9pin J.","year":"1995","unstructured":"P\u00e9pin J.; Milord F.; Khonde A.N.; Niyonsenga T.; Loko L.; Mpia B.; De Wals P.; Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995,89(1),92-97","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13071-019-3370-6","volume":"12","author":"Northover A.S.","year":"2019","unstructured":"Northover A.S.; Godfrey S.S.; Keatley S.; Lymbery A.J.; Wayne A.F.; Cooper C.; Pallant L.; Morris K.; Thompson R.C.A.; Increased Trypanosoma spp. richness and prevalence of haemoparasite co-infection following translocation. Parasit Vectors 2019,12(1),126","journal-title":"Parasit Vectors"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0972-9062.213454","volume":"49","author":"Udensi U.K.","year":"2012","unstructured":"Udensi U.K.; Fagbenro-Beyioku A.F.; Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice. J Vector Borne Dis 2012,49(3),143-150","journal-title":"J Vector Borne Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1590\/S0074-02762005000800002","volume":"100","author":"Dias J.C.P.","year":"2005","unstructured":"Dias J.C.P.; Schofield C.J.; Machado E.M.; Fernandes A.J.; Ticks, ivermectin, and experimental Chagas disease. Mem Inst Oswaldo Cruz 2005,100(8),829-832","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":", 105104.","DOI":"10.1016\/j.prevetmed.2020.105104","volume":"182","author":"Alves E.B.","year":"2020","unstructured":"Alves E.B.; Figueiredo F.B.; Rocha M.F.; Castro M.C.; Werneck G.L.; Effectiveness of insecticide-impregnated collars for the control of canine visceral leishmaniasis. Prev Vet Med 2020,182,, 105104.","journal-title":"Prev Vet Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","volume":"27","author":"Desjeux P.","year":"2004","unstructured":"Desjeux P.; Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004,27(5),305-318","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"Croft S.L.","year":"2006","unstructured":"Croft S.L.; Sundar S.; Fairlamb A.H.; Drug resistance in leishmaniasis. Clin Microbiol Rev 2006,19(1),111-126","journal-title":"Clin Microbiol Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1242\/jcs.185595","volume":"129","author":"Wetzel D.M.","year":"2016","unstructured":"Wetzel D.M.; Rhodes E.L.; Li S.; McMahon-Pratt D.; Koleske A.J.; The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. J Cell Sci 2016,129(16),3130-3143","journal-title":"J Cell Sci"},{"key":"ref=57","first-page":"252","volume":"4","author":"Vera-Izaguirre D.S.","year":"2006","unstructured":"Vera-Izaguirre D.S.; Vega-Memije E.; Quintanilla-Cedillo M.R.; Arenas R.; Leishmaniasis. A review. Dermatolog\u00eda Cosm\u00e9tica, M\u00e9dica Y Quir\u00fargica 2006,4(4),252-260","journal-title":"Dermatolog\u00eda Cosm\u00e9tica, M\u00e9dica Y Quir\u00fargica"},{"key":"ref=58","first-page":"51","volume":"36","author":"Miranda O.","year":"2007","unstructured":"Miranda O.; Gonz\u00e1lez I.; Leishmaniasis cut\u00e1nea. Presentaci\u00f3n de casos. Rev Cuba Med Mil 2007,36(4),51-54","journal-title":"Rev Cuba Med Mil"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"108059","DOI":"10.1016\/j.exppara.2020.108059","volume":"221","author":"Reis T.A.R.","year":"2021","unstructured":"Reis T.A.R.; Oliveira-da-Silva J.A.; Tavares G.S.V.; Mendon\u00e7a D.V.C.; Freitas C.S.; Costa R.R.; Lage D.P.; Martins V.T.; Machado A.S.; Ramos F.F.; Silva A.M.; Ludolf F.; Antinarelli L.M.R.; Brito R.C.F.; Ch\u00e1vez-Fumagalli M.A.; Humbert M.V.; Roatt B.M.; Coim-bra E.S.; Coelho E.A.F.; Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. Exp Parasitol 2021,221,108059","journal-title":"Exp Parasitol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4155\/tde-2020-0090","volume":"11","author":"Romero A.I.","year":"2020","unstructured":"Romero A.I.; Cid A.G.; Minetti N.E.; Briones Nieva C.A.; Garc\u00eda Bustos M.F.; Gonzo E.E.; Villegas M.; M Berm\u00fadez J.; Sustained-release hydrogels of ivermectin as alternative systems to improve the treatment of cutaneous leishmaniasis. Ther Deliv 2020,11(12),779-790","journal-title":"Ther Deliv"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/vbz.2009.0030","volume":"11","author":"Hanafi H.A.","year":"2011","unstructured":"Hanafi H.A.; Szumlas D.E.; Fryauff D.J.; El-Hossary S.S.; Singer G.A.; Osman S.G.; Watany N.; Furman B.D.; Hoel D.F.; Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major. Vector Borne Zoonotic Dis 2011,11(1),43-52","journal-title":"Vector Borne Zoonotic Dis"},{"key":"ref=62","first-page":"207","volume":"28","author":"Rasheid K.A.","year":"1998","unstructured":"Rasheid K.A.; Morsy T.A.; Efficacy of ivermectin on the infectivity of Leishmania major promastigotes. J Egypt Soc Parasitol 1998,28(1),207-212","journal-title":"J Egypt Soc Parasitol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1111\/j.1948-7134.2011.00122.x","volume":"36","author":"Mascari T.M.","year":"2011","unstructured":"Mascari T.M.; Clark J.; Gordon S.; Mitchell M.A.; Rowton E.D.; Stout R.; Foil L.D.; Oral treatment of rodents with insecticides for control of sand flies (Diptera: Psychodidae) and the Fluorescent Tracer Technique (FTT) as a tool to evaluate potential sand fly control methods. J Vector Ecol 2011,36(Suppl. 1),S132-S137","journal-title":"J Vector Ecol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/tmi.12870","volume":"22","author":"Gomez S.A.","year":"2017","unstructured":"Gomez S.A.; Picado A.; Systemic insecticides used in dogs: Potential candidates for phlebotomine vector control? Trop Med Int Health 2017,22(6),755-764","journal-title":"Trop Med Int Health"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0022-2011(88)90146-2","volume":"52","author":"Matha V.","year":"1988","unstructured":"Matha V.; Weiser J.; Molluscicidal effect of ivermectin on Biomphalaria glabrata. J Invertebr Pathol 1988,52(2),354-355","journal-title":"J Invertebr Pathol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":", e27119.","DOI":"10.1371\/journal.pone.0027119","volume":"6","author":"Taman A.","year":"2011","unstructured":"Taman A.; Ribeiro P.; Characterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoni. PLoS One 2011,6(11),, e27119.","journal-title":"PLoS One"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4269\/ajtmh.1994.51.83","volume":"51","author":"Fallon P.G.","year":"1994","unstructured":"Fallon P.G.; Doenhoff M.J.; Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 1994,51(1),83-88","journal-title":"Am J Trop Med Hyg"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.molbiopara.2018.12.005","volume":"228","author":"Sanchez M.C.","year":"2019","unstructured":"Sanchez M.C.; Cupit P.M.; Bu L.; Cunningham C.; Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni. Mol Biochem Parasitol 2019,228,6-15","journal-title":"Mol Biochem Parasitol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13071-019-3599-0","volume":"12","author":"Xu X.","year":"2019","unstructured":"Xu X.; Wang C.; Zhang S.; Huang Y.; Pan T.; Wang B.; Pan B.; Acaricidal efficacy of orally administered macrocyclic lactones against poultry red mites (Dermanyssus gallinae) on chicks and their impacts on mite reproduction and blood-meal digestion. Parasit Vectors 2019,12(1),345","journal-title":"Parasit Vectors"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jemermed.2013.05.014","volume":"45","author":"Sheele J.M.","year":"2013","unstructured":"Sheele J.M.; Anderson J.F.; Tran T.D.; Teng Y.A.; Byers P.A.; Ravi B.S.; Sonenshine D.E.; Ivermectin causes Cimex lectularius (bed-bug) morbidity and mortality. J Emerg Med 2013,45(3),433-440","journal-title":"J Emerg Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1590\/S0103-64402004000100015","volume":"15","author":"Shinohara E.H.","year":"2004","unstructured":"Shinohara E.H.; Martini M.Z.; de Oliveira Neto H.G.; Takahashi A.; Oral myiasis treated with ivermectin: Case report. Braz Dent J 2004,15(1),79-81","journal-title":"Braz Dent J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000495290","volume":"235","author":"Chandler D.J.","year":"2019","unstructured":"Chandler D.J.; Fuller L.C.; A review of scabies: An infestation more than skin deep. Dermatology 2019,235(2),79-90","journal-title":"Dermatology"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1203475420960446","volume":"25","author":"Richards R.N.","year":"2021","unstructured":"Richards R.N.; Scabies: Diagnostic and therapeutic update. J Cutan Med Surg 2021,25(1),95-101","journal-title":"J Cutan Med Surg"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4269\/ajtmh.20-1334","volume":"104","author":"Palaniappan V.","year":"2021","unstructured":"Palaniappan V.; Gopinath H.; Kaliaperumal K.; Crusted scabies. Am J Trop Med Hyg 2021,104(3),787-788","journal-title":"Am J Trop Med Hyg"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":", e13077.","DOI":"10.1111\/tid.13077","volume":"21","author":"Wang M.K.","year":"2019","unstructured":"Wang M.K.; Chin-Yee B.; Lo C.K.L.; Lee S.; El-Helou P.; Alowami S.; Gangji A.; Ribic C.; Crusted scabies in a renal transplant recipient treated with daily ivermectin: A case report and literature review. Transpl Infect Dis 2019,21(3),, e13077.","journal-title":"Transpl Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1086\/313942","volume":"31","author":"Bouchaud O.","year":"2000","unstructured":"Bouchaud O.; Houz\u00e9 S.; Schiemann R.; Durand R.; Ralaimazava P.; Ruggeri C.; Coulaud J-P.; Cutaneous larva migrans in travelers: A prospective study, with assessment of therapy with ivermectin. Clin Infect Dis 2000,31(2),493-498","journal-title":"Clin Infect Dis"},{"key":"ref=77","first-page":"111","volume":"72","author":"Brenner M.A.","year":"2003","unstructured":"Brenner M.A.; Patel M.B.; Cutaneous larva migrans: The creeping eruption. Cutis 2003,72(2),111-115","journal-title":"Cutis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/313787","volume":"30","author":"Caumes E.","year":"2000","unstructured":"Caumes E.; Treatment of cutaneous larva migrans. Clin Infect Dis 2000,30(5),811-814","journal-title":"Clin Infect Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/978-1-4471-6765-5_87","author":"Veraldi S.","year":"2016","unstructured":"Veraldi S.; \u00c7uka E.; Vaira F.; In: Abramovits, W; Graham, G; Har-Shai, Y; Strumia, R; Eds Dermatological Cryosurgery and Cryotherapy 2016,475-477","journal-title":"In: Abramovits, W; Graham, G; Har-Shai, Y; Strumia, R; Eds Dermatological Cryosurgery and Cryotherapy"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s40475-021-00239-0","volume":"8","author":"Rodriguez-Morales A.J.","year":"2021","unstructured":"Rodriguez-Morales A.J.; Gonz\u00e1lez-Leal N.; Montes-Montoya M.C.; Fern\u00e1ndez-Esp\u00edndola L.; Bonilla-Aldana D.K.; Aze\u00f1as-Burgoa J.M.; de Medina J.C.D.; Rotela-Fisch V.; Bermudez-Calderon M.; Arteaga-Livias K.; Larsen F.D.; Su\u00e1rez J.A.; Cutaneous larva migrans. Curr Trop Med Rep 2021,8(3),190-203","journal-title":"Curr Trop Med Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":", e12845.","DOI":"10.1111\/dth.12845","volume":"32","author":"Magri F.","year":"2019","unstructured":"Magri F.; Chello C.; Pranteda G.; Pranteda G.; Complete resolution of cutaneous larva migrans with topical ivermectin: A case report. Dermatol Ther 2019,32(3),, e12845.","journal-title":"Dermatol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-10-2467","volume":"17","author":"Kang W.","year":"2011","unstructured":"Kang W.; Tong J.H.; Chan A.W.; Lee T-L.; Lung R.W.; Leung P.P.; So K.K.; Wu K.; Fan D.; Yu J.; Sung J.J.; To K.F.; Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 2011,17(8),2130-2139","journal-title":"Clin Cancer Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"81062","DOI":"10.18632\/oncotarget.13188","volume":"7","author":"Sun D.","year":"2016","unstructured":"Sun D.; Li X.; He Y.; Li W.; Wang Y.; Wang H.; Jiang S.; Xin Y.; YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo. Oncotarget 2016,7(49),81062-81076","journal-title":"Oncotarget"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"107666","DOI":"10.18632\/oncotarget.22587","volume":"8","author":"Nambara S.","year":"2017","unstructured":"Nambara S.; Masuda T.; Nishio M.; Kuramitsu S.; Tobo T.; Ogawa Y.; Hu Q.; Iguchi T.; Kuroda Y.; Ito S.; Eguchi H.; Sugimachi K.; Saeki H.; Oki E.; Maehara Y.; Suzuki A.; Mimori K.; Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget 2017,8(64),107666-107677","journal-title":"Oncotarget"},{"key":"ref=85","first-page":"1","volume":"4","author":"Hashimoto H.","year":"2010","unstructured":"Hashimoto H.; Sudo T.; Maruta H.; Nishimura R.; The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov Ther 2010,4(1),1-4","journal-title":"Drug Discov Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/15548627.2020.1731266","volume":"17","author":"Feng X.","year":"2021","unstructured":"Feng X.; Zhang H.; Meng L.; Song H.; Zhou Q.; Qu C.; Zhao P.; Li Q.; Zou C.; Liu X.; Zhang Z.; Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy 2021,17(3),723-742","journal-title":"Autophagy"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1080\/15548627.2016.1231494","volume":"12","author":"Wang K.","year":"2016","unstructured":"Wang K.; Gao W.; Dou Q.; Chen H.; Li Q.; Nice E.C.; Huang C.; Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy 2016,12(12),2498-2499","journal-title":"Autophagy"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":", 118688.","DOI":"10.1016\/j.bbamcr.2020.118688","volume":"1867","author":"Boice A.","year":"2020","unstructured":"Boice A.; Bouchier-Hayes L.; Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res 2020,1867(6),, 118688.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1021\/acs.jafc.6b02812","volume":"64","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Luo M.; Xu W.; Yang M.; Wang B.; Gao J.; Li Y.; Tao L.; Avermectin confers its cytotoxic effects by inducing DNA damage and mitochondria-associated apoptosis. J Agric Food Chem 2016,64(36),6895-6902","journal-title":"J Agric Food Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":", e2599.","DOI":"10.1371\/journal.pone.0002599","volume":"3","author":"Pellegatti P.","year":"2008","unstructured":"Pellegatti P.; Raffaghello L.; Bianchi G.; Piccardi F.; Pistoia V.; Di Virgilio F.; Increased level of extracellular ATP at tumor sites: In vivo imaging with plasma membrane luciferase. PLoS One 2008,3(7),, e2599.","journal-title":"PLoS One"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"16222","DOI":"10.1038\/srep16222","volume":"5","author":"Draganov D.","year":"2015","unstructured":"Draganov D.; Gopalakrishna-Pillai S.; Chen Y-R.; Zuckerman N.; Moeller S.; Wang C.; Ann D.; Lee P.P.; Modulation of P2X4\/P2X7\/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep 2015,5(1),16222","journal-title":"Sci Rep"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","volume":"76","author":"Dou Q.","year":"2016","unstructured":"Dou Q.; Chen H-N.; Wang K.; Yuan K.; Lei Y.; Li K.; Lan J.; Chen Y.; Huang Z.; Xie N.; Zhang L.; Xiang R.; Nice E.C.; Wei Y.; Huang C.; Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt axis in breast cancer. Cancer Res 2016,76(15),4457-4469","journal-title":"Cancer Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"Anastas J.N.","year":"2013","unstructured":"Anastas J.N.; Moon R.T.; WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013,13(1),11-26","journal-title":"Nat Rev Cancer"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.15252\/emmm.201404084","volume":"6","author":"Melotti A.","year":"2014","unstructured":"Melotti A.; Mas C.; Kuciak M.; Lorente-Trigos A.; Borges I.; Ruiz i Altaba A.; The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med 2014,6(10),1263-1278","journal-title":"EMBO Mol Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/brain\/awv167","volume":"138","author":"Yin J.","year":"2015","unstructured":"Yin J.; Park G.; Lee J.E.; Choi E.Y.; Park J.Y.; Kim T-H.; Park N.; Jin X.; Jung J-E.; Shin D.; Hong J.H.; Kim H.; Yoo H.; Lee S.H.; Kim Y.J.; Park J.B.; Kim J.H.; DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis. Brain 2015,138(Pt 9),2553-2570","journal-title":"Brain"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/DDDT.S237393","volume":"14","author":"Liu J.","year":"2020","unstructured":"Liu J.; Zhang K.; Cheng L.; Zhu H.; Xu T.; Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin. Drug Des Devel Ther 2020,14,285-296","journal-title":"Drug Des Devel Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2016.10.064","volume":"480","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Fang S.; Sun Q.; Liu B.; Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun 2016,480(3),415-421","journal-title":"Biochem Biophys Res Commun"},{"year":"2018","key":"ref=98","unstructured":"World Health Organization World malaria report. Available from: 2018"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(04)01043-6","volume":"4","author":"Hay S.I.","year":"2004","unstructured":"Hay S.I.; Guerra C.A.; Tatem A.J.; Noor A.M.; Snow R.W.; The global distribution and population at risk of malaria: Past, present, and future. Lancet Infect Dis 2004,4(6),327-336","journal-title":"Lancet Infect Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":", CD012736.","DOI":"10.1002\/14651858.CD012736.pub2","volume":"8","author":"Choi L.","year":"2019","unstructured":"Choi L.; Majambere S.; Wilson A.L.; Larviciding to prevent malaria transmission. Cochrane Database Syst Rev 2019,8(8),, CD012736.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":", CD013117.","DOI":"10.1002\/14651858.CD013117","volume":"6","author":"de Souza D.K.","year":"2021","unstructured":"de Souza D.K.; Larbi I.; Boakye D.A.; Okebe J.; Ivermectin treatment in humans for reducing malaria transmission. Cochrane Database Syst Rev 2021,6(6),, CD013117.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1242\/jeb.118570","volume":"218","author":"Meyers J.I.","year":"2015","unstructured":"Meyers J.I.; Gray M.; Kuklinski W.; Johnson L.B.; Snow C.D.; Black W.C.; Partin K.M.; Foy B.D.; Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol 2015,218(Pt 10),1478-1486","journal-title":"J Exp Biol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"40232","DOI":"10.1074\/jbc.R112.406280","volume":"287","author":"Wolstenholme A.J.","year":"2012","unstructured":"Wolstenholme A.J.; Glutamate-gated chloride channels. J Biol Chem 2012,287(48),40232-40238","journal-title":"J Biol Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S0140-6736(18)32613-8","volume":"393","author":"Chaccour C.","year":"2019","unstructured":"Chaccour C.; Rabinovich N.R.; Advancing the repurposing of ivermectin for malaria. Lancet 2019,393(10180),1480-1481","journal-title":"Lancet"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cpt.1716","volume":"107","author":"Kobylinski K.C.","year":"2020","unstructured":"Kobylinski K.C.; Jittamala P.; Hanboonkunupakarn B.; Pukrittayakamee S.; Pantuwatana K.; Phasomkusolsil S.; Davidson S.A.; Winterberg M.; Hoglund R.M.; Mukaka M.; van der Pluijm R.W.; Dondorp A.; Day N.P.J.; White N.J.; Tarning J.; Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects. Clin Pharmacol Ther 2020,107(5),1221-1230","journal-title":"Clin Pharmacol Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/1475-2875-13-417","volume":"13","author":"Alout H.","year":"2014","unstructured":"Alout H.; Krajacich B.J.; Meyers J.I.; Grubaugh N.D.; Brackney D.E.; Kobylinski K.C.; Diclaro J.W.; Bolay F.K.; Fakoli L.S.; Diabat\u00e9 A.; Dabir\u00e9 R.K.; Bougma R.W.; Foy B.D.; Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J 2014,13(1),417","journal-title":"Malar J"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12936-015-0691-6","volume":"14","author":"Chaccour C.J.","year":"2015","unstructured":"Chaccour C.J.; Rabinovich N.R.; Slater H.; Canavati S.E.; Bousema T.; Lacerda M.; Ter Kuile F.; Drakeley C.; Bassat Q.; Foy B.D.; Establishment of the ivermectin research for malaria elimination network: Updating the research agenda. Malar J 2015,14,243","journal-title":"Malar J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13071-015-0735-3","volume":"8","author":"Derua Y.A.","year":"2015","unstructured":"Derua Y.A.; Kisinza W.N.; Simonsen P.E.; Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasit Vectors 2015,8(1),130","journal-title":"Parasit Vectors"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.2011.11-0160","volume":"85","author":"Kobylinski K.C.","year":"2011","unstructured":"Kobylinski K.C.; Sylla M.; Chapman P.L.; Sarr M.D.; Foy B.D.; Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg 2011,85(1),3-5","journal-title":"Am J Trop Med Hyg"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"G\u00f6tz V.","year":"2016","unstructured":"G\u00f6tz V.; Magar L.; Dornfeld D.; Giese S.; Pohlmann A.; H\u00f6per D.; Kong B-W.; Jans D.A.; Beer M.; Haller O.; Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep 2016,6(1),1-15","journal-title":"Sci Rep"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/jac\/dks147","volume":"67","author":"Mastrangelo E.","year":"2012","unstructured":"Mastrangelo E.; Pezzullo M.; De Burghgraeve T.; Kaptein S.; Pastorino B.; Dallmeier K.; de Lamballerie X.; Neyts J.; Hanson A.M.; Frick D.N.; Bolognesi M.; Milani M.; Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 2012,67(8),1884-1894","journal-title":"J Antimicrob Chemother"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.diagmicrobio.2019.03.012","volume":"95","author":"Ketkar H.","year":"2019","unstructured":"Ketkar H.; Yang L.; Wormser G.P.; Wang P.; Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis 2019,95(1),38-40","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00705-015-2653-2","volume":"161","author":"Lee Y.J.","year":"2016","unstructured":"Lee Y.J.; Lee C.; Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Arch Virol 2016,161(2),257-268","journal-title":"Arch Virol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.antiviral.2013.10.004","volume":"100","author":"Lundberg L.","year":"2013","unstructured":"Lundberg L.; Pinkham C.; Baer A.; Amaya M.; Narayanan A.; Wagstaff K.M.; Jans D.A.; Kehn-Hall K.; Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res 2013,100(3),662-672","journal-title":"Antiviral Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.antiviral.2015.12.012","volume":"126","author":"Varghese F.S.","year":"2016","unstructured":"Varghese F.S.; Kaukinen P.; Gl\u00e4sker S.; Bespalov M.; Hanski L.; Wennerberg K.; K\u00fcmmerer B.M.; Ahola T.; Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res 2016,126,117-124","journal-title":"Antiviral Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":", e0006934.","DOI":"10.1371\/journal.pntd.0006934","volume":"12","author":"Xu T-L.","year":"2018","unstructured":"Xu T-L.; Han Y.; Liu W.; Pang X-Y.; Zheng B.; Zhang Y.; Zhou X-N.; Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl Trop Dis 2018,12(11),, e0006934.","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=117","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1341","author":"Ooi E.E.","year":"2021","unstructured":"Ooi E.E.; Repurposing Ivermectin as an Anti-Dengue Drug 2021","journal-title":"Repurposing Ivermectin as an Anti-Dengue Drug"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1042\/BJ20120150","volume":"443","author":"Wagstaff K.M.","year":"2012","unstructured":"Wagstaff K.M.; Sivakumaran H.; Heaton S.M.; Harrich D.; Jans D.A.; Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012,443(3),851-856","journal-title":"Biochem J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1515\/hsz-2015-0171","volume":"396","author":"Kosyna F.K.","year":"2015","unstructured":"Kosyna F.K.; Nagel M.; Kluxen L.; Kraushaar K.; Depping R.; The importin \u03b1\/\u03b2-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways. Biol Chem 2015,396(12),1357-1367","journal-title":"Biol Chem"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/bcp.14476","volume":"87","author":"Pe\u00f1a\u2010Silva R.","year":"2021","unstructured":"Pe\u00f1a\u2010Silva R.; Duffull S.B.; Steer A.C.; Jaramillo\u2010Rincon S.X.; Gwee A.; Zhu X.; Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID\u201019. Br J Clin Pharmacol 2021,87(3),1589-1590","journal-title":"Br J Clin Pharmacol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":", 104787.","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"Caly L.","year":"2020","unstructured":"Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020,178,, 104787.","journal-title":"Antiviral Res"},{"key":"ref=122","first-page":", CD015017.","volume":"7","author":"Popp M.","year":"2021","unstructured":"Popp M.; Stegemann M.; Metzendorf M-I.; Gould S.; Kranke P.; Meybohm P.; Skoetz N.; Weibel S.; Ivermectin for preventing and treating COVID\u201019. Cochrane Database Syst Rev 2021,7(7),, CD015017.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=123","unstructured":"U.S. Food and drug administration FDA Letter to Stakeholders: Do Not Use Ivermectin Intended for Animals as Treatment for COVID-19 in Humans. Available from: https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans"},{"author":"Stefan Kluge U.J.","key":"ref=124","unstructured":"Stefan Kluge U.J.; Available from:(Accessed on: 10\/10\/2021)"},{"journal-title":"World Health Organization Therapeutics and COVID-19: living guideline Available from:","key":"ref=125","unstructured":"World Health Organization Therapeutics and COVID-19: living guideline Available from: (Accessed on: 10\/10\/2021)."},{"journal-title":"National Institutes of Health COVID-19 Treatment Guidelines Available from:","key":"ref=126","unstructured":"National Institutes of Health COVID-19 Treatment Guidelines Available from: (Accessed on: 10\/10\/2021)."},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/AAC.01696-12","volume":"57","author":"Lim L.E.","year":"2013","unstructured":"Lim L.E.; Vilch\u00e8ze C.; Ng C.; Jacobs W.R.; Ram\u00f3n-Garc\u00eda S.; Thompson C.J.; Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 2013,57(2),1040-1046","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":", e0003549.","DOI":"10.1371\/journal.pntd.0003549","volume":"9","author":"Omansen T.F.","year":"2015","unstructured":"Omansen T.F.; Porter J.L.; Johnson P.D.; van der Werf T.S.; Stienstra Y.; Stinear T.P.; In-vitro activity of avermectins against Mycobacterium ulcerans. PLoS Negl Trop Dis 2015,9(3),, e0003549.","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/jac\/dkt089","volume":"68","author":"Muhammed Ameen S.","year":"2013","unstructured":"Muhammed Ameen S.; Drancourt M.; Ivermectin lacks antituberculous activity. J Antimicrob Chemother 2013,68(8),1936-1937","journal-title":"J Antimicrob Chemother"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.amepre.2011.06.045","volume":"41","author":"Bouchery E.E.","year":"2011","unstructured":"Bouchery E.E.; Harwood H.J.; Sacks J.J.; Simon C.J.; Brewer R.D.; Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 2011,41(5),516-524","journal-title":"Am J Prev Med"},{"year":"2012","key":"ref=131","unstructured":"World Health Organization World Health Statistics. Available from: 2012"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","volume":"75","author":"Johnson B.A.","year":"2008","unstructured":"Johnson B.A.; Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 2008,75(1),34-56","journal-title":"Biochem Pharmacol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuron.2012.09.024","volume":"76","author":"Khakh B.S.","year":"2012","unstructured":"Khakh B.S.; North R.A.; Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 2012,76(1),51-69","journal-title":"Neuron"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1085\/jgp.200910336","volume":"135","author":"Toulme E.","year":"2010","unstructured":"Toulme E.; Garcia A.; Samways D.; Egan T.M.; Carson M.J.; Khakh B.S.; P2X4 receptors in activated C8-B4 cells of cerebellar micro-glial origin. J Gen Physiol 2010,135(4),333-353","journal-title":"J Gen Physiol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1085\/jgp.200308986","volume":"123","author":"Priel A.","year":"2004","unstructured":"Priel A.; Silberberg S.D.; Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol 2004,123(3),281-293","journal-title":"J Gen Physiol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.110.167908","volume":"334","author":"Asatryan L.","year":"2010","unstructured":"Asatryan L.; Popova M.; Perkins D.; Trudell J.R.; Alkana R.L.; Davies D.L.; Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. J Pharmacol Exp Ther 2010,334(3),720-728","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11064-014-1271-9","volume":"39","author":"Wyatt L.R.","year":"2014","unstructured":"Wyatt L.R.; Finn D.A.; Khoja S.; Yardley M.M.; Asatryan L.; Alkana R.L.; Davies D.L.; Contribution of P2X4 receptors to ethanol intake in male C57BL\/6 mice. Neurochem Res 2014,39(6),1127-1139","journal-title":"Neurochem Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/WNR.0000000000000211","volume":"25","author":"Yardley M.M.","year":"2014","unstructured":"Yardley M.M.; Neely M.; Huynh N.; Asatryan L.; Louie S.G.; Alkana R.L.; Davies D.L.; Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport 2014,25(13),1018-1023","journal-title":"Neuroreport"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00213-018-4869-9","volume":"235","author":"Khoja S.","year":"2018","unstructured":"Khoja S.; Huynh N.; Warnecke A.M.P.; Asatryan L.; Jakowec M.W.; Davies D.L.; Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl) 2018,235(6),1697-1709","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/molecules26061791","volume":"26","author":"Silva J.","year":"2021","unstructured":"Silva J.; Carry E.; Xue C.; Zhang J.; Liang J.; Roberge J.Y.; Davies D.L.; A novel dual drug approach that combines ivermectin and dihydromyricetin (DHM) to reduce alcohol drinking and preference in mice. Molecules 2021,26(6),1791","journal-title":"Molecules"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/2230-973X.114897","volume":"3","author":"Bala R.","year":"2013","unstructured":"Bala R.; Pawar P.; Khanna S.; Arora S.; Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig 2013,3(2),67-76","journal-title":"Int J Pharm Investig"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.alcohol.2015.03.006","volume":"49","author":"Yardley M.M.","year":"2015","unstructured":"Yardley M.M.; Huynh N.; Rodgers K.E.; Alkana R.L.; Davies D.L.; Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol 2015,49(6),553-559","journal-title":"Alcohol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":", e001350.","DOI":"10.1136\/openhrt-2020-001350","volume":"7","author":"DiNicolantonio J.J.","year":"2020","unstructured":"DiNicolantonio J.J.; Barroso J.; McCarty M.; Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart 2020,7(2),, e001350.","journal-title":"Open Heart"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","volume":"73","author":"Kaur H.","year":"2021","unstructured":"Kaur H.; Shekhar N.; Sharma S.; Sarma P.; Prakash A.; Medhi B.; Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol Rep 2021,73(3),736-749","journal-title":"Pharmacol Rep"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","volume":"60","author":"Yan S.","year":"2011","unstructured":"Yan S.; Ci X.; Chen N.; Chen C.; Li X.; Chu X.; Li J.; Deng X.; Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res 2011,60(6),589-596","journal-title":"Inflamm Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijantimicag.2019.05.003","volume":"54","author":"Ashour D.S.","year":"2019","unstructured":"Ashour D.S.; Ivermectin: From theory to clinical application. Int J Antimicrob Agents 2019,54(2),134-142","journal-title":"Int J Antimicrob Agents"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/10837450.2016.1200078","volume":"22","author":"Starkloff W.J.","year":"2017","unstructured":"Starkloff W.J.; Bucal\u00e1 V.; Palma S.D.; Gonzalez Vidal N.L.; Design and in vitro characterization of ivermectin nanocrystals liquid formulation based on a top-down approach. Pharm Dev Technol 2017,22(6),809-817","journal-title":"Pharm Dev Technol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40262-015-0242-x","volume":"54","author":"Pathak K.","year":"2015","unstructured":"Pathak K.; Raghuvanshi S.; Oral bioavailability: Issues and solutions via nanoformulations. Clin Pharmacokinet 2015,54(4),325-357","journal-title":"Clin Pharmacokinet"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00436-013-3696-5","volume":"113","author":"Ali M.","year":"2014","unstructured":"Ali M.; Afzal M.; Verma M.; Bhattacharya S.M.; Ahmad F.J.; Samim M.; Abidin M.Z.; Dinda A.K.; Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model. Parasitol Res 2014,113(2),681-691","journal-title":"Parasitol Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":", 8043983.","DOI":"10.1155\/2016\/8043983","volume":"2016","author":"Croci R.","year":"2016","unstructured":"Croci R.; Bottaro E.; Chan K.W.K.; Watanabe S.; Pezzullo M.; Mastrangelo E.; Nastruzzi C.; Liposomal systems as nanocarriers for the antiviral agent ivermectin. Int J Biomater 2016,2016,, 8043983.","journal-title":"Int J Biomater"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13071-019-3719-x","volume":"12","author":"Ahmadpour E.","year":"2019","unstructured":"Ahmadpour E.; Godrati-Azar Z.; Spotin A.; Norouzi R.; Hamishehkar H.; Nami S.; Heydarian P.; Rajabi S.; Mohammadi M.; Perez-Cordon G.; Nanostructured lipid carriers of ivermectin as a novel drug delivery system in hydatidosis. Parasit Vectors 2019,12(1),469","journal-title":"Parasit Vectors"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00436-017-5510-2","volume":"116","author":"Ullio-Gamboa G.","year":"2017","unstructured":"Ullio-Gamboa G.; Palma S.; Benoit J.P.; Allemandi D.; Picollo M.I.; Toloza A.C.; Ivermectin lipid-based nanocarriers as novel formulations against head lice. Parasitol Res 2017,116(8),2111-2117","journal-title":"Parasitol Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-015-0150-8","volume":"16","author":"Deeks E.D.","year":"2015","unstructured":"Deeks E.D.; Ivermectin: A review in rosacea. Am J Clin Dermatol 2015,16(5),447-452","journal-title":"Am J Clin Dermatol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":", 110823.","DOI":"10.1016\/j.colsurfb.2020.110823","volume":"189","author":"Das S.","year":"2020","unstructured":"Das S.; Lee S.H.; Chia V.D.; Chow P.S.; Macbeath C.; Liu Y.; Shlieout G.; Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. Colloids Surf B Biointerfaces 2020,189,, 110823.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/21691401.2017.1307207","volume":"46","author":"Guo D.","year":"2018","unstructured":"Guo D.; Dou D.; Li X.; Zhang Q.; Bhutto Z.A.; Wang L.; Ivermection-loaded solid lipid nanoparticles: Preparation, characterisation, stability and transdermal behaviour. Artif Cells Nanomed Biotechnol 2018,46(2),255-262","journal-title":"Artif Cells Nanomed Biotechnol"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220516163242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204874\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220516163242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T04:57:58Z","timestamp":1727240278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204874\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":155,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220516163242","relation":{},"ISSN":["1567-2018"],"issn-type":[{"type":"print","value":"1567-2018"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}